Projects

Senior Research Fellow
MVDr. Štefan Bezek, DrSc.

International

Finished
  • Targeting Molecular Pathways of Glucolipotoxicity by a Novel Carboxymethylated Mercaptotriazinoindole Inhibitor of Aldo-Keto Reductase AKR1B1 In Diabetes, Inflammation and Age-related Neurodegeneration
    Program: Bilateral - other
    Duration: 1. 5. 2016 – 30. 4. 2019

National

Current
  • Neuroprotective and cardioprotective potential of phenol acids in the prevention of civilization diseases
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
Finished
  • The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • Innovative approaches in toxicology of ageing
    Program: SRDA
    Duration: 1. 7. 2019 – 30. 6. 2023
  • Effect of fructose diet in experimental models of metabolic syndrome and in healthy subjects: proposal of effective pharmacological treatment
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Redox Homeostasis, Proteostasis and Inflammation as Potential Targets For Influencing Ageing and Age-Related Diseases: Modulation by the compounds of natural and synthetic origin
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Pharmacological intervention in glucose-toxicity in type 2 diabetes
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Risk factors of cardiovascular and cerebrovascular diseases and pharmacological possibilities of their influence
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • The study of mechanisms and possible early detection of embryofetal damage caused by intrauterine perinatal hypoxia
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 10. 2014
  • Experimental models of perinatal asphyxia in evaluation of behavioral disorders and possibility of pharmacological intervention
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Developmental Origin of Metabolic Syndrome:Hypertension, Diabetes and Dyslipidemia
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Ischaemia and reperfusion in experimental diabetes type 2 and possibilities of pharmacological management
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Contribution to prevention and treatment of behavioural disorders evoked by hypotic-ischaemic damage of the brain in perinatal period: experimental model of asphyxia and administration of substances with antiradical and antioxidative effects
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees